166 related articles for article (PubMed ID: 20456731)
1. Proton pump inhibitors: predisposers to Alzheimer disease?
Fallahzadeh MK; Borhani Haghighi A; Namazi MR
J Clin Pharm Ther; 2010 Apr; 35(2):125-6. PubMed ID: 20456731
[TBL] [Abstract][Full Text] [Related]
2. Can proton pump inhibitors accentuate skin aging?
Namazi MR; Jowkar F
Arch Med Res; 2010 Feb; 41(2):147-8. PubMed ID: 20470945
[TBL] [Abstract][Full Text] [Related]
3. Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease.
Bamberger ME; Landreth GE
Microsc Res Tech; 2001 Jul; 54(2):59-70. PubMed ID: 11455613
[TBL] [Abstract][Full Text] [Related]
4. Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for augmentation of beta-amyloid-induced microglia-mediated neurotoxicity.
Li M; Pisalyaput K; Galvan M; Tenner AJ
J Neurochem; 2004 Nov; 91(3):623-33. PubMed ID: 15485493
[TBL] [Abstract][Full Text] [Related]
5. Lysosome regulation of microglia in Alzheimer's disease via TFEB-vacuolar ATPase.
Nat Neurosci; 2024 Jan; 27(1):13-14. PubMed ID: 38001269
[No Abstract] [Full Text] [Related]
6. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils.
Majumdar A; Cruz D; Asamoah N; Buxbaum A; Sohar I; Lobel P; Maxfield FR
Mol Biol Cell; 2007 Apr; 18(4):1490-6. PubMed ID: 17314396
[TBL] [Abstract][Full Text] [Related]
7. Microglia as a potential bridge between the amyloid beta-peptide and tau.
Kitazawa M; Yamasaki TR; LaFerla FM
Ann N Y Acad Sci; 2004 Dec; 1035():85-103. PubMed ID: 15681802
[TBL] [Abstract][Full Text] [Related]
8. Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients.
Grigolon A; Cantù P; Savojardo D; Conte D; Penagini R
J Clin Gastroenterol; 2008 Oct; 42(9):969-73. PubMed ID: 18719508
[TBL] [Abstract][Full Text] [Related]
9. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes.
Blasko I; Stampfer-Kountchev M; Robatscher P; Veerhuis R; Eikelenboom P; Grubeck-Loebenstein B
Aging Cell; 2004 Aug; 3(4):169-76. PubMed ID: 15268750
[TBL] [Abstract][Full Text] [Related]
10. Unexpected consequences of proton pump inhibitor use.
Altman KW; Radosevich JA
Otolaryngol Head Neck Surg; 2009 Nov; 141(5):564-6. PubMed ID: 19861191
[TBL] [Abstract][Full Text] [Related]
11. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro.
Veerhuis R; Van Breemen MJ; Hoozemans JM; Morbin M; Ouladhadj J; Tagliavini F; Eikelenboom P
Acta Neuropathol; 2003 Feb; 105(2):135-44. PubMed ID: 12536224
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitor use and enteric infections.
Dial MS
Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S10-6. PubMed ID: 19262540
[TBL] [Abstract][Full Text] [Related]
13. Human truncated tau is using a different mechanism from amyloid-beta to damage the blood-brain barrier.
Kovac A; Zilkova M; Deli MA; Zilka N; Novak M
J Alzheimers Dis; 2009; 18(4):897-906. PubMed ID: 19749439
[TBL] [Abstract][Full Text] [Related]
14. Morphologically distinct types of amyloid plaques point the way to a better understanding of Alzheimer's disease pathogenesis.
D'Andrea MR; Nagele RG
Biotech Histochem; 2010 Apr; 85(2):133-47. PubMed ID: 20121465
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.
Ouar Z; Bens M; Vignes C; Paulais M; Pringel C; Fleury J; Cluzeaud F; Lacave R; Vandewalle A
Biochem J; 2003 Feb; 370(Pt 1):185-93. PubMed ID: 12435274
[TBL] [Abstract][Full Text] [Related]
16. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation.
Koistinaho M; Kettunen MI; Goldsteins G; Keinänen R; Salminen A; Ort M; Bures J; Liu D; Kauppinen RA; Higgins LS; Koistinaho J
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1610-5. PubMed ID: 11818564
[TBL] [Abstract][Full Text] [Related]
17. Is there a dark side to long-term proton pump inhibitor therapy?
Nealis TB; Howden CW
Am J Ther; 2008; 15(6):536-42. PubMed ID: 19127138
[TBL] [Abstract][Full Text] [Related]
18. Is the Use of Proton-pump Inhibitors a Risk Factor for Alzheimer's Disease? Molecular Mechanisms and Clinical Implications.
Ide K; Matsuoka N; Kawakami K
Curr Med Chem; 2018; 25(18):2166-2174. PubMed ID: 29376492
[TBL] [Abstract][Full Text] [Related]
19. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
Miner PB
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
[TBL] [Abstract][Full Text] [Related]
20. Clearing amyloid through the blood-brain barrier.
Zlokovic BV
J Neurochem; 2004 May; 89(4):807-11. PubMed ID: 15140180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
